oHSV2-PD-L1/CD3-BsAb Administered Via Intratumoral Injection

NCT05938296 · clinicaltrials.gov ↗

PHASE1

Phase

SUSPENDED

Status

29

Enrollment

INDUSTRY

Sponsor class

Stopped Strategy adjustment

Conditions

Solid Tumor

Interventions

DRUG: BS006 Injection

Sponsor

Binhui Biopharmaceutical Co., Ltd.